Doctors Offer New Treatment Of Parkinson’s Disease. Part 3 of 3

One other expert agreed that more study is needed. “As a phase 2 study, this treaty was not designed to demonstrate whether or not treatment with inosine delayed need for symptomatic therapy for Parkinson’s disease,” said Dr Steven Frucht, a professor of neurology and director of the movement disorders unit at Mount Sinai School of Medicine, in New York City. “A phase 3 trial will be needed to demonstrate whether or not oral inosine helps fight Parkinson’s, or even has the hidden to delay the need for symptomatic treatment” vigrx plus.

Parts: 1 2 3